enVVeno expects 9 SAVVE trial sites active; shareholders approve director elections, plan amendments

enVVeno Medical Corp

Elected Dr. Francis Duhay and Dr. Sanjay Shrivastava as Class I directors for terms ending at 2024 annual meeting.
Ratified Marcum LLP as independent auditor for FY2021 with 6,085,415 for, 11,290 against, 9,074 abstain.
Approved amendment to 2016 Omnibus Incentive Plan increasing authorized shares to 4,500,000 (2,458,617 for, 1,254,579 against).
Approved evergreen provision requiring at least 20% fully diluted shares under plan (2,439,885 for, 1,273,777 against).
By end of week, expects 9 sites active and enrolling in SAVVE U.S. pivotal trial for VenoValve.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.